GSK plc vs Pfizer Inc.: Strategic Comparison

This in-depth comparison examines GSK plc and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching GSK plc on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between GSK plc and Pfizer Inc. is widest.

On the headline numbers, GSK plc reports annual revenue of ~$43.1B against $62.6B for Pfizer Inc., while their respective market capitalizations stand at $100.0B and $160.3B. GSK plc is headquartered in United Kingdom and Pfizer Inc. operates from United States, and those different home markets shape how each company competes.

GSK plc: GSK plc is listed in London (LSE: GSK) and New York (NYSE: GSK) and is a FTSE 100 constituent. It operates in about 70 countries with 33 manufacturing sites and about 66,800 employees. The company focuses on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Well-known products include Shingrix, Arexvy, Trelegy Ellipta, Ventolin, Nucala, Dovato and Cabenuva.

Pfizer Inc.: Pfizer Inc. (NYSE: PFE) is one of the largest pharmaceutical companies in the world by revenue, headquartered at The Spiral, 66 Hudson Boulevard East, New York. It employs about 75,000 people and sells medicines in more than 180 countries. Its history includes Terramycin, Lipitor (via Warner-Lambert), Viagra, Prevnar (via Wyeth) and the Comirnaty COVID-19 vaccine developed with BioNTech.

GSK plc and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between GSK plc and Pfizer Inc..

GSK plc business model: GSK makes money by discovering, manufacturing and selling prescription medicines and vaccines, mostly to health systems, insurers, pharmacies and governments. Its sales are reported in three groups. Specialty Medicines (~$17.8 billion (£13.5 billion) in 2025, about 41% of sales) covers HIV through ViiV Healthcare, respiratory and immunology biologics such as Nucala and Exdensur, and oncology drugs such as Jemperli, Ojjaara and Blenrep. Vaccines (~$12.1 billion (£9.2 billion), about 28%) are led by Shingrix for shingles, the Bexsero and Menveo meningitis vaccines and the Arexvy RSV vaccine. General Medicines (~$13.2 billion (£10.0 billion), about 31%) includes established inhalers such as Trelegy and Ventolin and antibiotics like Augmentin. GSK also earns royalty income on licensed products.

Pfizer Inc. business model: Pfizer makes money by selling patented prescription medicines and vaccines to wholesalers, hospitals, governments and pharmacies, with the United States as its largest market. Revenue is concentrated in large franchises such as Eliquis (co-commercialized with Bristol Myers Squibb), the Prevnar pneumococcal vaccines, the Vyndaqel tafamidis family, Ibrance, Xtandi and the Seagen antibody-drug conjugates. Pfizer funds internal R&D but sources much of its pipeline externally through acquisitions (Seagen, Metsera) and licensing deals (Innovent, 3SBio), then uses its regulatory, manufacturing and commercial scale to launch products globally during their exclusivity window.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of GSK plc stack up against those of Pfizer Inc..

GSK plc competitive advantage: GSK's advantages are scale in vaccine manufacturing, a long-acting HIV portfolio through ViiV Healthcare, and the AS01 adjuvant system used in Shingrix and Arexvy. Vaccines are hard to copy because they depend on biological manufacturing, cold-chain distribution and long-term government contracts. ViiV's long-acting injectables, Cabenuva for treatment and Apretude for prevention, aim to move patients onto newer regimens ahead of the dolutegravir patent expiry.

Pfizer Inc. competitive advantage: Pfizer's advantage is scale in late-stage development, regulatory filings, manufacturing and commercialization. The BioNTech partnership showed it: BioNTech supplied the mRNA science, while Pfizer ran the global Phase 3 trial with more than 40,000 participants, built ultra-cold distribution and manufactured billions of Comirnaty doses. That capability also makes Pfizer a natural buyer or partner for smaller biotechs that lack global reach.

Future prospects matter as much as current results. The growth strategies below explain how GSK plc and Pfizer Inc. each plan to expand from here.

GSK plc growth strategy: Under Luke Miels, GSK is combining targeted acquisitions with faster R&D. Deals since 2025 include IDRx (GIST, January 2025), efimosfermin from Boston Pharmaceuticals ($1.2 billion upfront, July 2025) and Nuvalent ($10.6 billion, completed July 2026). In July 2026 GSK identified 7 assets across 18 indications in oncology, respiratory, hepatology and vaccines to speed up, raised its 2026 phase III start target from 10 to more than 20, and launched a cost programme to fund that investment.

Pfizer Inc. growth strategy: Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total). Obesity: Pfizer acquired Metsera in November 2025 for about $10 billion including contingent value rights, after a bidding contest with Novo Nordisk. Cost: a multi-year cost realignment and manufacturing optimization program funds R&D and protects margins.

A closer look at the financial trajectory of GSK plc and Pfizer Inc. rounds out the comparison.

GSK plc: GSK reported 2025 turnover of ~$43.2 billion (£32.7 billion) (+4% at actual rates, +7% at constant currency), operating profit of ~$10.4 billion (£7.9 billion), profit attributable to shareholders of ~$7.52 billion (£5.7 billion), and earnings per share of 141.1p. Cash generated from operations was ~$11.7 billion (£8.9 billion) and free cash flow ~$5.28 billion (£4.0 billion). In Q2 2026, sales rose 5% to ~$11.1 billion (£8.4 billion) and core operating profit rose 7% to ~$3.7 billion (£2.8 billion), beating consensus, while reported operating profit fell to ~$635 million (£481 million) because of the camlipixant impairment. H1 2026 turnover was ~$21.1 billion (£16.0 billion). GSK reaffirmed 2026 guidance of 3% to 5% turnover growth and 7% to 9% core operating profit growth, expects a 70p dividend for 2026, and launched a three-year plan targeting ~$2.51 billion (£1.9 billion) of annual savings by 2029.

Pfizer Inc.: Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%.